Breaking Through Blind Spots in Rare Cancer Research via Direct Patient Engagement and Genomic Result Return Systems
Background
Cancer genomics has advanced dramatically since the Cancer Genome Atlas (TCGA) project. In common cancers such as lung and breast cancer, the accumulation of large-scale patient data has facilitated the rapid establishment of targeted therapies tailored to individual patients. In contrast, rare and refractory cancers with low incidence remain in a molecular blind spot. This is because it is difficult to collect a sufficient number of tissue samples at the level of a single medical institution to ensure statistical significance. Existing large-scale projects have mainly relied on a one-way approach of collecting residual surgical specimens from large research hospitals. The patients who were the subjects of the study remained merely as sample providers, and there was a structural disconnect in which even genomic analysis results were not shared with the patients themselves. This created a vicious cycle in which marginalized patient populations with poor geographic accessibility or limited opportunities to participate in research were excluded from genomic cohorts. This acted as a major factor delaying the discovery of novel drug targets for rare cancers. The background behind the need for a research paradigm in which patients participate as research partners and analysis results are returned to them.
Key Findings
The Participant Engagement and Cancer Genome Sequencing (PE-CGS) network, launched under the National Cancer Institute (NCI) Cancer Moonshot initiative, places direct partnership with patients at its center. The research team organically integrated the entire cycle of patient recruitment, specimen collection, multi-omics analysis, and result return into three specialized units. The Participant Engagement Unit (PEU) is activated in collaboration with patient organizations to enhance participant engagement. The Genome Characterization Unit (GCU) precisely decoded rare cancer tumor tissues and normal cell DNA using whole-exome sequencing (WES) and RNA-Seq pipelines. The Engagement Optimization Unit (EOU) quantitatively evaluates the impact of genomic analysis results on patients' psychological stability and decision-making. The most notable advancement is the establishment of a remote registration system in which patients receive saliva or blood collection kits by mail at their place of residence. This secured a pathway for patients to register regardless of their residence or whether they are outpatients at large hospitals. Variants with established clinical validity were delivered to patients along with genetic counseling after re-verification through Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. This achievement institutionalized procedures that reconcile the dual challenges of protecting patient rights and collecting high-quality data.
Significance and Prospects
The data constructed by the PE-CGS network is sequentially released to the Genomic Data Commons (GDC) of the U.S. National Institutes of Health (NIH), where it is shared with researchers worldwide as a research asset. The accumulated reproductive cell and tumor genome profiles are expected to provide clues that accelerate target discovery and drug repurposing research. This represents an ethical turning point in research, shifting patients from passive subjects of observation to active research collaborators. Clear practical challenges remain to be overcome. Guidelines should follow to reduce the confusion and emotional burden that arise when explaining variants of uncertain significance (VUS) with unclear clinical significance to patients. Securing research funding to maintain remote registration systems long-term and standardizing analysis across laboratories are also ongoing areas for verification. When such institutional improvements are implemented in parallel, patient-centered genomic research will become a sustainable driving force for overcoming rare diseases. The attempt to complete the genomic map of neglected cancers functions as a practical stepping stone that expands the foundation of public precision medicine—a robust bridge that broadens clinical trial access for minority patients with no other treatment options.
Nature Genetics, Published online: 04 November 2026; doi:10.1038/s41588-026-02800-xThe Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network integrates participant engagement, return of genomic results and comprehensive data collection to advance cancer genomics research involving rare and understudied cancers.
This network model is directly utilized to shorten the development timelines for rare cancer drugs in pharmaceutical and biotech companies and clinical settings. Because patients' genomic information is known from the registration stage, it facilitates the design of precision basket trials by enabling the rapid recruitment of patient cohorts with specific target variants into clinical trials. It is an alternative that can substantially reduce the development period of rare targeted anticancer drugs, which had been stagnant for years due to delays in clinical trial enrollment. Furthermore, the variant return system linked with genetic counseling directly leads to practical clinical benefits, such as secondary cancer prevention and early diagnosis for patients and their families. Pharmaceutical companies will save on the cost of sample acquisition required for companion diagnostics (CDx) kit development and biomarker discovery, leveraging accumulated multi-omics data from rare cancers. It establishes a virtuous cycle where research participation leads to optimized diagnosis and treatment.